摘要
目的探讨α糖苷酶抑制剂与二肽基肽酶-4(DPP-4)抑制剂联合治疗T2DM患者的有效性及安全性。方法将120例T2DM患者随机分为观察组和对照组,各60例。观察组采用α糖苷酶抑制剂与DPP-4抑制剂联合治疗,对照组单独应用DPP-4抑制剂治疗,随访16周,测定治疗前后血糖及生化指标,观察不良反应发生情况及治疗对C-RP的影响。结果治疗后,观察组FPG[(9.02±1.11)vs(7.14±1.41)mmol/L]、2hPG[(15.28±1.08)vs(9.85±1.59)mmol/L]、HbA_1c[(8.24±1.92)%vs(6.68±1.24)%]及C-RP[(8.82±1.71)vs(5.14±1.21)mg/L]水平降低;观察组HbA_1c的达标率高于对照组[76.67%(46/60)vs 63.33%(38/60)](P<0.05)。两组血糖指标和C-RP水平治疗前后差值(Δ值)比较,差异有统计学意义(P<0.05)。结论α糖苷酶抑制剂与DPP-4抑制剂联合应用与单独应用DPP-4抑制剂相比,治疗T2DM效果更好,且降低血清C-RP效果更佳。
Objective To investigate the efficacy and safety ofα-glucosidase inhibitor in combination with DPP-4 inhibitor on type 2 diabetes mellitus. Methods A total of 120 patients with T2DM were randomly divided into two groups：observation group usingα-glucosidase inhibitor in combination with DPP-4 inhibitor（n=60）and control group treated with DPP-4 inhibitor monotherapy（n=60）.All patients were followed up for 16 weeks.Blood glucose and biochemical indices were measured at baseline and after treatment.Adverse events and effect of treatment on C-RP were observed. Results After treatment,FPG[（9.02±1.11）vs（7.14±1.41）mmol/L],2hPG[（15.28±1.08）vs（9.85±1.59）mmol/L],HbA_1c[（8.24±1.92）% vs（6.68±1.24）%]and C-RP level[（8.82±1.71）vs（5.14±1.21）mg/L]were lower in observation group than in control group.Proportion of patients with targeted HbA_1c was higher in observation group than in control group[76.67%（46/60）vs 63.33%（38/60）]（P〈0.05）.The differences（Δvalue）of blood glucose indicators and C-RP level between baseline and after-treatment in both groups were statistically significant（P〈0.05）. Conclusion α-glucosidase inhibitor in combination with DPP-4 inhibitor has a better effect on T2DM treatment and C-RP level than DPP-4 inhibitor monotherapy.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2015年第12期1070-1072,共3页
Chinese Journal of Diabetes
